Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00340808 · ClinicalTrials.gov registry record

Molecular Staging of Endometrial Cancer

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
5,492
Enrollment target

NCT00340808: Completed study, sponsored by National Cancer Institute (NCI).

NCT00340808 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 5,492 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00340808 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
5,492 participants
Enrollment target

Study Summary

This study, sponsored by NCI and the Gynecologic Oncology Group (GOG), will collect tissue samples from women with cancer of the endometrium (lining of the uterus). Researchers will use the samples to learn more about endometrial cancer and develop new treatments and methods of prevention. Women with endometrial cancer who are suitable candidates for surgery and who have not had prior retroperitoneal surgery or pelvic or abdominal radiation therapy may be eligible for this study. Candidates will be screened with a medical history and physical examination, blood tests, and endometrial biopsy (surgical removal of a small tissue sample) or dilation and curettage (D \& C). Participants will undergo hysterectomy (surgery to remove the uterus) along with removal of both fallopian tubes and ovaries. This is the standard surgical treatment for endometrial cancer. Lymph nodes in the pelvis near the main blood vessel in the abdomen are also removed to determine if the disease has spread to these nodes. If cancer is found involving other sites, the cancer in those areas may also be removed; examination of the tissues will determine if further therapy beyond surgery is needed. Before surgery, patients will complete a 20-minute questionnaire that includes questions about their background, reproductive history, menstruation and menopause, certain surgeries, birth control pills and hormone replacement therapy, other drugs and medicines, weight and height, smoking, medical history, and family history of cancer. Some of the tissue removed during surgery, plus a urine sample collected from a catheter bag during surgery, and blood drawn before surgery and at follow-up visits 6 weeks and 3 years after surgery, will be sent to the GOG Tissue Bank in Columbus, Ohio. This bank stores, processes, and distributes biological specimens from patients that agree to participate in studies conducted by the GOG. Patients will have follow-up visits 6 weeks after surgery, then every 6 months fo

Trial Details

FieldValue
Enrollment Target 5,492 participants
Start Date 2004-03-19
Est. Completion 2020-07-16
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00340808 record still lists

NCT00340808 is an observational study that tracks outcomes without assigning an intervention. Its 5,492 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT00340808 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00340808 about?

NCT00340808 is a clinical study titled "Molecular Staging of Endometrial Cancer". This study, sponsored by NCI and the Gynecologic Oncology Group (GOG), will collect tissue samples from women with cancer of the endometrium (lining of the uterus). Researchers will use the samples to learn more about endometrial cancer and develop new treatments and methods of prevention. Women wi...

What is the current status of trial NCT00340808?

This trial is currently completed. The enrollment target is 5,492 participants. The study started on 2004-03-19. Estimated completion is 2020-07-16.

Who is sponsoring clinical trial NCT00340808?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05952557 · 5,500 participants · Phase 3

    An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

  • NCT06084234 · 5,500 participants · Phase 4

    National Liver Cancer Screening Trial

  • NCT04295486 · 5,478 participants · Phase 2

    Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

  • NCT07146568 · 5,515 participants · NA

    Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00340808, the US trial registry maintained by the National Library of Medicine. NCT00340808 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.